Endotoxic shock model with fluid resuscitation in Macaca mulatta.
These studies established a macaque model of early-phase endotoxic shock, and investigated the resuscitation effects of three different solutions. Twenty-four macaques were assigned to four groups. Nineteen animals were given an intravenous dose of 2.8 mg/kg lipopolysaccharide (LPS). At 60 min after LPS challenge, the animals were given (i) 5 mL/kg normal saline (Ns group, n=6), (ii) 5% of 5 mL/kg sodium bicarbonate (Sb group, n=6), (iii) hypertonic 3.5% sodium chloride of 5 mL/kg (Hs group, n=7). The control group (Co group, n=5) was first injected with 1 mL/kg Ns and with 5 mL/kg Ns 60 min later. Haemodynamic parameters and blood gases were measured during the experiment, and myocardial morphology was examined on termination of the experiment. Administration of LPS caused hypotension and decreases of the left ventricular work index (LVWI). In the Sb group, mean arterial pressure, cardiac index, systemic vascular resistance index, LVWI and right ventricular work index were significantly higher than those of the Ns group. Pathological changes of myocardium were identified in all of the LPS groups. The studies suggest that macaques are suitable models for studying endotoxic shock and potential fluid therapies.
Yin
Guo Qing
GQ
The Second Hospital of Nanjing, affiliated with Medical College, Southeast University, 1-1 Zhongfu Road, Nanjing, Jiangsu, 210003, People's Republic of China. yinguoq@jlonline.com
Qiu
Hai Bo
HB
Du
Kai He
KH
Tang
Jia Qi
JQ
Lu
Cheng Ping
CP
Fang
Zhi Xun
ZX
D000704:Analysis of Variance; D000818:Animals; D001784:Blood Gas Analysis; D004195:Disease Models, Animal; D006439:Hemodynamics / Q000187:drug effects; D006493:Heparin; D006863:Hydrogen-Ion Concentration; D008070:Lipopolysaccharides / Q000633:toxicity*; D008253:Macaca mulatta / Q000502:physiology*; D009206:Myocardium / Q000473:pathology; D012462:Saline Solution, Hypertonic / Q000494:pharmacology / Q000627:therapeutic use; D012772:Shock, Septic / Q000139:chemically induced / Q000188:drug therapy*; D017693:Sodium Bicarbonate / Q000494:pharmacology / Q000627:therapeutic use; D016277:Ventricular Function, Left / Q000187:drug effects
D008070:Lipopolysaccharides; D012462:Saline Solution, Hypertonic; D017693:Sodium Bicarbonate; D006493:Heparin